RBM10 and lung carcinoma: To test this hypothesis, first we performed functional genetic experiments by RBM10 knockdown (KD) and overexpression (OE) in patient-derived lung cancer cell lines to assess cell viability and apoptotic responses to the EGFR kinase inhibitor osimertinib, which we used at clinically relevant concentrations (32).